GLP-1 Medications Comparison Chart 2026: Complete Guide

Seven FDA-approved GLP-1 medications are now available for diabetes and weight management, and they differ in ways that matter: dosing frequency, weight loss results, cost, and side effect profiles. Our GLP-1 comparison chart below breaks down every major option so you can walk into your next appointment knowing exactly what to ask.

What Are GLP-1 Medications and How Do They Compare?

GLP-1 receptor agonists are a class of medications that mimic incretin hormones naturally produced in your intestines. These hormones regulate blood sugar by stimulating insulin release when glucose levels rise and slowing gastric emptying to help you feel full longer. This dual mechanism makes them effective for both diabetes management and weight loss.

Seven FDA-approved GLP-1 medications are currently available: semaglutide (Ozempic, Wegovy, Rybelsus), tirzepatide (Mounjaro, Zepbound), dulaglutide (Trulicity), exenatide (Byetta, Bydureon), liraglutide (Victoza, Saxenda), and lixisenatide (Adlyxin). Each offers different injection frequencies, with options ranging from daily to weekly dosing. All GLP-1 medications need gradual dose increases to limit side effects.

The medications differ significantly in their mechanisms. While most target only GLP-1 receptors, tirzepatide uniquely activates both GLP-1 and GIP receptors, potentially explaining its superior effectiveness. Both branded and compounded versions exist, though only FDA-approved medications guarantee consistent potency and safety standards.

When to Consider Each GLP-1 Medication Option

The choice of GLP-1 medication depends on your primary treatment goals and individual circumstances. Ozempic and Rybelsus work best for patients focused primarily on diabetes management with moderate weight loss as a secondary benefit. These semaglutide-based options provide excellent blood sugar control with average weight loss of 12-15%.

Wegovy and Zepbound are specifically approved for obesity treatment and deliver more dramatic weight loss results. Zepbound (tirzepatide) trial participants lost 15-22% of body weight. Wegovy participants lost about 15% at the 2.4 mg dose and about 19% at the 7.2 mg dose (Wegovy HD) over 72 weeks in the STEP UP trial.

Trulicity and Victoza suit patients preferring established safety profiles with longer market histories. These medications have extensive cardiovascular outcome data, making them ideal for patients with heart disease concerns. Your doctor can help determine whether GLP-1 therapy fits alongside your current treatment plan.

Daily injection options like liraglutide work well for patients who prefer more frequent dosing control, while weekly injections offer convenience for busy lifestyles.

How GLP-1 Medications Work and Dosing Schedules

GLP-1 medications follow different dosing patterns that affect both effectiveness and side effects. Weekly injections include semaglutide, tirzepatide, and dulaglutide, while daily options include liraglutide and oral semaglutide (Rybelsus). The injection frequency doesn't necessarily correlate with effectiveness, but it does impact lifestyle considerations.

Dose escalation protocols vary significantly between medications. Most start with low doses and increase gradually over 4-12 weeks to minimize gastrointestinal side effects. Semaglutide starts at 0.25 mg weekly for both Ozempic and Wegovy. Ozempic is typically increased to 1 mg or 2 mg for diabetes, while Wegovy is increased to 2.4 mg over about 16 weeks for weight management. As of March 2026, adults who have tolerated Wegovy 2.4 mg for at least 4 weeks and need additional weight loss can step up to Wegovy HD (7.2 mg). It is not a starting dose. Tirzepatide begins at 2.5 mg weekly and can reach 15 mg over 12-16 weeks.

The dual-receptor mechanism of tirzepatide sets it apart from single-action GLP-1 medications. By targeting both GLP-1 and GIP pathways, it provides enhanced glucose control and appetite suppression. This explains why patients often see superior results compared to traditional GLP-1 medications.

Injection pen mechanisms also differ between manufacturers. Some use pre-filled pens while others require cartridge insertion. Needle sizes vary from 4mm to 8mm, affecting comfort levels for different patients. Understanding these practical differences helps ensure successful long-term treatment adherence.

Effectiveness and Weight Loss Results by GLP-1 Medication

Clinical trial data reveals significant differences in effectiveness between GLP-1 medications. Tirzepatide participants lost 15-22% of body weight in major studies. In the 72-week STEP UP trial, semaglutide 7.2 mg produced an average 18.7% weight loss, compared with 15.6% for semaglutide 2.4 mg and 3.9% for placebo. Older options like liraglutide average 8-12%. Tirzepatide and semaglutide 7.2 mg have not been compared directly in a head-to-head trial.

HbA1c reduction varies from 1.5-2.4% across different medications, with tirzepatide again showing superior glycemic control. Most patients reach maximum effectiveness between 12-20 weeks, depending on the medication and final dose achieved. The gradual titration process means patience is required to see full benefits.

Cardiovascular benefits have been established for semaglutide and dulaglutide through dedicated outcome trials. These medications reduce major adverse cardiac events by 13-26% in high-risk patients. Tirzepatide's dedicated cardiovascular outcome trial (SURPASS-CVOT) has also reported results.

Real-world effectiveness often mirrors clinical trial results, though individual responses vary considerably. Factors like adherence, diet, exercise, and baseline health status significantly influence outcomes. Some patients respond better to certain medications due to genetic or metabolic differences.

What to Know About the Higher Wegovy Dose

Wegovy HD (semaglutide 7.2 mg) is the highest-dose semaglutide injection approved for weight loss. In the STEP UP trial, the extra weight loss came with more side effects than the 2.4 mg dose. Nausea was reported by 43.7% of participants on 7.2 mg versus 38.3% on 2.4 mg, and vomiting by 24.8% versus 16.4%. One side effect stood out: dysesthesia, an altered skin sensation such as tingling, burning, or unusual skin sensitivity, occurred in 22.9% of participants on 7.2 mg compared with 6.0% on 2.4 mg and 0.5% on placebo. About 5.4% of participants on 7.2 mg stopped treatment because of side effects, compared with 4.0% on 2.4 mg. Moving to the higher dose is a trade-off between added weight loss and added side effects, which is why it is reserved for people who have already tolerated 2.4 mg and still need further weight reduction.

GLP-1 Medication Cost and Insurance Coverage Compared

Cost is one of the most practical factors in any GLP-1 comparison chart, and the differences between medications can be significant. List prices without insurance typically range from roughly $900 to $1,400 per month for branded injectable options like Ozempic, Wegovy, Mounjaro, and Zepbound. Older agents such as Trulicity and Victoza sit at the lower end of that range, while newer dual-receptor options tend to carry higher sticker prices.

Insurance coverage changes the picture considerably. Many commercial plans cover GLP-1 medications prescribed for type 2 diabetes, which means Ozempic and Mounjaro are more consistently covered than Wegovy and Zepbound, which carry obesity-specific indications. Patients with employer-sponsored insurance who are prescribed a GLP-1 for diabetes can often bring their monthly out-of-pocket cost down to $25 or less using manufacturer savings cards.

Coverage for Weight Loss vs. Diabetes

Medicare Part D currently does not cover GLP-1 medications prescribed solely for weight loss, though coverage for diabetes indications is available. Medicaid coverage varies by state. This distinction matters because the same active ingredient, semaglutide, is sold as Ozempic for diabetes and as Wegovy for obesity, and insurers treat them differently.

For patients without coverage, compounded semaglutide and tirzepatide became widely available during the FDA shortage period, at costs sometimes 60-80% lower than branded versions. However, the FDA has warned that compounded versions are not held to the same manufacturing standards as FDA-approved drugs, and shortages of branded agents have been largely resolved as of 2025.

How to Find Out What You Will Pay

The fastest way to get a real number is to run a prior authorization check with your insurer before your doctor writes the prescription. Most plans require documentation of a qualifying diagnosis, a BMI threshold, or evidence that lifestyle interventions have been tried. Our AI doctor can help you understand what documentation is typically required and what questions to bring to your prescriber, so you are prepared before the visit rather than surprised after.

Frequently Asked Questions

Which GLP-1 medication causes the most weight loss?

Tirzepatide (sold as Zepbound for obesity and Mounjaro for diabetes) produced the highest average weight loss in clinical trials, with participants losing 15-22% of body weight, and it outperformed semaglutide 2.4 mg in a head-to-head study. Wegovy's newer 7.2 mg dose produced an average 18.7% weight loss over 72 weeks, but it has not been compared directly with tirzepatide. Individual results depend on dose, adherence, diet, and exercise habits.

What is the difference between Ozempic, Wegovy, and Mounjaro?

Ozempic and Wegovy both contain semaglutide, but Ozempic is FDA-approved for type 2 diabetes while Wegovy is approved for chronic weight management. Mounjaro contains tirzepatide, a dual GLP-1 and GIP receptor agonist approved for type 2 diabetes. In head-to-head trials against semaglutide 2.4 mg, tirzepatide produced greater weight loss and HbA1c reduction. Wegovy is now also available in a 7.2 mg dose (Wegovy HD) for adults who need more weight loss after tolerating 2.4 mg.

How much do GLP-1 medications cost without insurance?

Without insurance, most branded GLP-1 injectable medications cost between $900 and $1,400 per month at list price. Manufacturer savings cards can reduce costs to as low as $25 per month for eligible patients with commercial insurance. Compounded versions have been available at lower prices, but FDA-approved branded medications offer more consistent quality standards.

Are GLP-1 medications covered by Medicare for weight loss?

As of 2025, Medicare Part D does not cover GLP-1 medications prescribed solely for obesity or weight loss. Coverage is available when the medication is prescribed for type 2 diabetes. Legislation to expand Medicare coverage for obesity treatments has been proposed but had not been enacted as of this writing.

What side effects do GLP-1 medications have in common?

Nausea, vomiting, diarrhea, and constipation are the most common side effects shared across GLP-1 medications. These effects are usually most pronounced during dose escalation and tend to improve over time. Less common but more serious risks include pancreatitis and, in patients with a personal or family history of certain thyroid cancers, a potential thyroid tumor risk noted in animal studies.

The Bottom Line

GLP-1 medications offer proven benefits for both diabetes management and weight loss, with clear differences in effectiveness, dosing, and cost between options. Tirzepatide has produced the largest weight loss in head-to-head trials against semaglutide 2.4 mg, while semaglutide now offers a higher 7.2 mg dose alongside established cardiovascular benefits. Cost considerations significantly impact accessibility, with insurance coverage and manufacturer programs essential for affordability. The choice between medications should balance clinical effectiveness, side effect tolerance, dosing convenience, and financial factors. Success requires proper medical supervision, gradual dose titration, and realistic expectations about timeline and results. Doctronic's AI-powered platform can help you understand these options and discuss which GLP-1 medication aligns best with your health goals and circumstances. Ready to take control of your health? Get started with Doctronic today.